#Class Action #Treace Medical #Pomerantz LLP

Pomerantz Law Firm Issues Investor Alert on Treace Medical Concepts

Recently, the Pomerantz Law Firm announced a class action lawsuit targeting Treace Medical Concepts, Inc., trading under the symbol TMCI on NASDAQ. This lawsuit has been filed due to allegations that Treace Medical, along with specific officers and directors, have potentially engaged in securities fraud and other illegal business practices. Investors who sustained losses in Treace Medical are prompted to take action as soon as possible, as time is of the essence in this situation.

Who Should Take Action?

Investors who experienced financial losses through purchasing Treace Medical securities during the Class Period should act promptly. The Pomerantz Law Firm recommends that affected individuals reach out directly to Danielle Peyton via phone at 646-581-9980 or via email at [email protected]. When contacting the firm, investors are encouraged to provide their mailing address, phone number, and the number of shares purchased to facilitate the process of possibly joining the class action.

Key Deadlines

The critical deadline for investors to request the Court to appoint them as Lead Plaintiff is June 10, 2025. This opportunity is crucial for those who feel they fit the criteria and wish to be more actively involved in the proceedings.

The Background

On May 7, 2024, just after the market closed, Treace Medical issued a significant press release that adjusted its full-year revenue projections for 2024. The new forecast indicated a drop in expected revenue from between $220 million and $225 million down to a range of $201 million to $211 million. This announcement followed claims made during an earnings call that the company was facing heightened competition from minimally invasive osteotomy procedures and